Cogent Biosciences (COGT) highlighted the company’s key 2026 milestones ahead of its presentation at J.P. Morgan’s 44th annual healthcare conference. Key highlights: New Drug Application for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026; NDA submission for GIST on track for April 2026; bezuclastinib has the potential to be the first new therapy for second-line GIST in over 20 years; clinical data presentations from all three pivotal trials, PEAK, SUMMIT and APEX, expected at major medical meetings in 1H 2026; Investigational New Drug applications expected in 2026 for potentially best-in-class pan-KRAS(ON) and selective JAK2 V617F inhibitors; Strong financial position with ~$900 million cash to begin 2026, sufficient to fund commercial launches and operations well into 2028.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Aligos Therapeutics initiated with a Buy at UBS
- Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Favorable FDA Outlook Underpin Upgraded $52 Buy Rating
- Cogent Biosciences price target raised to $52 from $50 at H.C. Wainwright
- Cogent Biosciences submits NDA for bezuclastinib in NonAdvSM
- Cogent Biosciences price target raised to $67 from $65 at JPMorgan